ROSETREES: Personalised ultraviolet B (UVB) treatment of psoriasis
Research type
Research Study
Full title
Personalised ultraviolet B (UVB) treatment of psoriasis through biomarker integration with computational modelling of psoriatic plaque resolution.
IRAS ID
217936
Contact name
Nick Reynolds
Contact email
Sponsor organisation
Newcastle upon Tyne Hospitals Foundation Trust
Clinicaltrials.gov Identifier
R&D Reference, 8207
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
Psoriasis is a long-term inflammatory skin disease characterized by well-defined, thick and scaly plaques that affects quality of life and may be associated with arthritis and cardiovascular disease. Whole-body UVB phototherapy is one of the few treatments that can
clear psoriasis. Notably, the clinical effect in the UVB spectrum is restricted to the wavelength range of 300-313nm and UV lamps were developed that could emit a narrow range of UV radiation with peak emission at 311nm (narrow-band UVB [NbUVB)).
Nevertheless, individual patient response and length of remission is variable and currently unpredictable. The aims of this study are to (1) develop biomarkers (including baseline clinical features) that predict which patients will do well with NbUVB and which patients are
likely to remain clear for longer; (2) use computer models to optimise protocols for the delivery of NbUVB phototherapy and 3) perform a feasibility study of modified and personalised NbUVB phototherapy regimes. Patients with psoriasis who have been
prescribed NbUVB phototherapy as part of routine standard care will be given the opportunity to participate.There will be three main groups of patients in the study. The clinical pathway and phototherapy regimes for groups one and two will follow current clinical practice and phototherapy protocols. Biomarkers in skin and blood predictive of clinical response (derived
in group 1) will be validated in group 2. These data will be analysed through computational modelling, enabling systematic study of the contribution of key biomarkers on psoriasis clearance. We will then model the effects of key parameters, including rate of increase of
UVB doses and time intervals between phototherapy doses, in the context of individual patient data, and develop algorithms that compute more efficient, effective and personalised UVB treatment regimes. These newly derived regimes will then be tested in a feasibility clinical study (group 3).REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
17/NE/0045
Date of REC Opinion
6 Apr 2017
REC opinion
Further Information Favourable Opinion